Targeted Pulse Quiz: September 15

Foran Goes Beyond the Basics of BPDCN

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading experts.

Jordyn Sava;James M. Foran, MD

September 17th 2024

Atypical Chronic Myeloid Leukemia: A Rare Disease With Poor Prognosis

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

Listen

Massimo Breccia, MD

Tarantino Covers HER2-Low Breast Cancer and Antibody-Drug Conjugates

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Jordyn Sava;Paolo Tarantino, MD

August 30th 2024

From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and treatment.

Listen

Jordyn Sava

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

Key Advances in Oncology: Top Highlights From ESMO 2024

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination with azacitidine and venetoclax in AML.

Related Content

Foran Goes Beyond the Basics of BPDCN

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading experts.

Jordyn Sava;James M. Foran, MD

September 17th 2024

Atypical Chronic Myeloid Leukemia: A Rare Disease With Poor Prognosis

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

Listen

Massimo Breccia, MD

Tarantino Covers HER2-Low Breast Cancer and Antibody-Drug Conjugates

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

Jordyn Sava;Paolo Tarantino, MD

August 30th 2024

From ABVD to Nivolumab-AVD: New Treatment Strategies in Hodgkin Lymphoma

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and treatment.

Listen

Jordyn Sava

FDA Grants Fast Track Designation to ICT01 Plus Azacitidine and Venetoclax in AML

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.